Skip to main content
SpringerLink
Log in

Treatment strategies in acute myeloid leukemia (AML)

B. Second line treatment

  • Review article
  • Published:
Blut Aims and scope Submit manuscript

Summary

The strategy for treatment of relapsed or refractory acute myeloid leukemia must primarily be based on the patient's age and clinical condition as well as on the stage of the disease. Accordingly, the general decision between an intensive approach including high-dose chemotherapy or possibly immediate allogeneic bone marrow transplantation versus less-aggressive palliative treatment will precede the selection of the most appropriate salvage regimen. In patients qualifying for intensive second-line chemotherapy the duration of the first remission and the number of relapses provide the means to discriminate between refractoriness or maintained responsiveness to conventional protocols. More than 50% of patients with first relapses after 6–12 months remission duration will respond to standard therapy again and should therefore not be entered on investigational agents with unproven antileukemic activity. The latter seems deeply warranted, on the other hand, for early relapses, second recurrences and resistant first relapses with a remission rate of less than 30% after conventional regimens. These guidelines not only provide an objective rationale for selecting the most appropriate strategy at relapse in individual patients. Furthermore, they facilitate interstudy comparisons and a better judgement of different treatment protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amadori S, Papa G, Avvisati G, Fenu S, Monarca B, Petu MC, Pulsoni A, Mandelli F (1984) Sequential combination of high-dose Ara-C (Hi DAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma. Leuk Res 8: 729–735

    Google Scholar 

  2. Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F (1989) Phase II trial of intermediate dose Ara-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukemia 3: 112–114

    Google Scholar 

  3. Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, Young CW (1980) Phase I and II trial of 4′-(9-acridinyl-amino) methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res 40: 3304–3306

    Google Scholar 

  4. Arlin ZA, Silver R, Cassileth P, Armentrout S, Gams R, Daghestani A, Coleman M, Schoch I, Dukart G (1985) Phase I–II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61–64

    Google Scholar 

  5. Arlin ZA, Gaddipati J, Ahmed T, Mittelman A, Friedland M, Rieber E (1985) Treatment of acute leukemia with amsacrine and high-dose cytarabine. Cancer Treat Rep 69: 1001–1002

    Google Scholar 

  6. Arnold AM (1979) Podophyllotoxin derivative VP 16-213. Cancer Chemother Pharmacol 3: 71–80

    Google Scholar 

  7. Bartram CR, Ludwig WD, Hiddemann W, Lyons J, Buschle M, Ritter J, Harbott J, Fröhlich A, Janssen WG (1989) Acute myeloid leukemia: Analysis of ras gene mutations and clonality defined by polymorphic x-linked loci. Leukemia 3: 247–256

    Google Scholar 

  8. Bartram CR, Janssen JWG (1990) Clonal analysis of human leukemias by molecular genetic approaches. In: Büchner Th, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — Prognostic factors and treatment strategies II. Springer, Berlin Heidelberg New York Tokyo (in press)

    Google Scholar 

  9. Bennett JM, Lymann GH, Cassileth PA, Glick JH, Oken M (1984) A phase II trial of VP-16-213 in adults with refractory acute myeloid leukemia. Am J Clin Oncol 7: 471–473

    Google Scholar 

  10. Bernasconi C, Lazzarino M, Morra E (1982) Etoposide (VP 16-213) in the treatment of acute monocytic and myelo-monocytic leukemias. Chimotherapia 1: 181–185

    Google Scholar 

  11. Bolwell BJ, Cassileth PA, Gale RP (1987) Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: A review. Leukemia 1: 575–579

    Google Scholar 

  12. Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DAG (1987) Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. Cancer Treat Rep 71: 161–163

    Google Scholar 

  13. Büchner Th, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589

    Google Scholar 

  14. Buckner CD, Sanders J, Appelbaum FR (1989) Allogeneic marrow transplantation for acute non-lymphoblastic leukemia: first remission versus after first relapse. Bone Marrow Transplant 4: 244–246

    Google Scholar 

  15. Burnett AK (1988) Autologous bone marrow transplantation in acute leukemia. Leuk Res 12: 531–536

    Google Scholar 

  16. Cantin G, Brennan JK (1984) High-dose cytosine arabinoside for acute nonlymphocytic leukemia. Am J Hematol 16: 59–66

    Google Scholar 

  17. Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR (1988) Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia — a Cancer and Leukemia Group B Study. J Clin Oncol 6: 499–508

    Google Scholar 

  18. Carella AM, Santini G, Martinengo M, Giordano D, Nati S, Congiu A, Cerri R, Risso M, Damasio E, Rossi E, Vimercati R, Pacciarini MA, Marmont AM (1985) 4-demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. Cancer 55: 1452–1454

    Google Scholar 

  19. Champlin R, Gale RP (1987) Bone marrow transplantation for acute leukemia: Recent advances and comparison with alternative therapies. Semin Hematol 24: 55–67

    Google Scholar 

  20. Chan HY, Meyers FJ, Lewis JP (1987) High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 20: 265–266

    Google Scholar 

  21. Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864

    Google Scholar 

  22. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR et al. (1987) The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2: 243–258

    Google Scholar 

  23. McCulloch EA, Buick RN, Curtis JE, Messner HA, Senn JS (1981) The heritable nature of clonal characteristics in acute myeloblastic leukemia. Blood 58: 105–109

    Google Scholar 

  24. Dabich L, Bull FE, Beltran G, Athens JW, Coltman C Jr, Weick JK, van Slyck EJ, Amare M (1986) Phase II evaluation of aclarubicin in refractory adult acute leukemia: A Southwest Oncology Group Study. Cancer Treat Rep 70: 967–969

    Google Scholar 

  25. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408–1412

    Google Scholar 

  26. Decker RW, Ho WG, Champlin RE (1987) Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia. Cancer Treat Rep 71: 881–882

    Google Scholar 

  27. Dicke A, for the Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR) (1986) Current status of bone marrow transplantation (BMT) for acute myelogenous leukemia (AML). Proc Am Soc Clin Oncol 5: 167

    Google Scholar 

  28. Dicke KA, Spinolo JA (1989) High dose therapy and autologous bone marrow transplant (ABMT) in acute leukemia: Is purging necessary? Bone Marrow Transplant 4: 184–186

    Google Scholar 

  29. Early AP, Preisler HD, Higby DJ, Brecher M, Browman G, McBride JA (1982) High-dose cytosine arabinoside. Clinical response to therapy in acute leukemia. Med Pediat Oncol [Suppl 1]: 239–250

    Google Scholar 

  30. Ehninger G, Ho AD, Meyer P, Mjaaland I, Ostendorf P, Seither E (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Onkologie 8: 146–148

    Google Scholar 

  31. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389–390

    Google Scholar 

  32. Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ (1984) Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol 2: 102–106

    Google Scholar 

  33. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ (1987) Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1: 580–583

    Google Scholar 

  34. Evans JPM, Prentice HG (1982) Remission induction in acute myeloid leukaemia with oral etoposide. Lancet II: 1345–1346

    Google Scholar 

  35. Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B (1986) Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphoblastic leukemia. N Engl J Med 315: 15–24

    Google Scholar 

  36. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R (1987) Clonal development, stem-cell differentiation and clinical remissions in acute nonlymphocytic leukemia. New Engl J Med 317: 468–473

    Google Scholar 

  37. Fiebig HH, Henß H, Engelhardt R, Hoelzer D, Pralle H, Link H, Schmitz R (1983) Phase-II-Studie von AMSA bei Erwachsenen mit therapierefraktären akuten Leukämien. Onkologie 6: 188–190

    Google Scholar 

  38. Fière D, Campos L, Van HV, Guyotat D, Archimbaud E, Extra JM, Coiffier B, Viala JJ, Bryon PA, Milan JJ, Ritouet D (1986) Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. Cancer Treat Rep 70: 285–286

    Google Scholar 

  39. Frei III E, Sallan SE (1978) Acute lymphoblastic leukemia: Treatment. Cancer 42: 828–838

    Google Scholar 

  40. Freund M, Link H, Diedrich H, Wilke HJ, Schmoll HJ, Poliwoda H (1987) High-dose Ara-C and etoposide in the treatment of refractory or relapsing acute leukemia. Blut 55: 215

    Google Scholar 

  41. Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300: 1189–1199

    Google Scholar 

  42. Gale RP (1987) The role of bone marrow transplantation in acute myelogenous leukemia. In: Büchner Th, Schellong G, Hiddemann W, Urbanitz D, Ritter J (eds) Acute leukemias — Prognostic factors and treatment strategies. Springer, Berlin Heidelberg New York London Paris Tokyo, pp 197–203

    Google Scholar 

  43. Gale RP, Butturini A (1989) Autotransplants in leukaemia. Lancet II: 315–317

    Google Scholar 

  44. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB et al. (1989) Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 73: 2209–2218

    Google Scholar 

  45. Goldie JH, Coldman AJ (1985) Genetic instability in the development of drug resistance. Semin Oncol 12: 222–230

    Google Scholar 

  46. Gorin NC, Aegerter P, Auvert B for the EBMTG (1989) Autologous bone marrow transplantation (ABMT) for acute leukemia in remission: fifth European survey. Evidence in favour of marrow purging. Bone Marrow Transplant 4: 206

    Google Scholar 

  47. Gorin NC, Aegerter P, Auvert B for the EBMTG (1990) Autologous bone marrow transplantation (ABMT) for acute leukemia in remission: an analysis on 1322 cases. In: Büchner Th, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — Prognostic factors and treatment strategies II. Springer, Heidelberg Berlin New York Tokyo (in press)

    Google Scholar 

  48. Greidanus J, de Vries EGE, Mulder NH, Sleijfer DT, Uges DRA, Oosterhuis B, Willemse PHB (1989) A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 7: 790–797

    Google Scholar 

  49. Hakami N, Look AT, Steuber PC, Krischer J, Castleberry R, Harris R, Ravindranath Y, Vietti TJ (1987) Combined etoposide and 5-azacytidine in children and adolescents with refractory and relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 5: 1022–1025

    Google Scholar 

  50. Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, Le Prise PY, Monconduit M, Jaubert J, Carcassone Y (1987) Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat Rep 71: 991–992

    Google Scholar 

  51. Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N for the French Study Group of Idarubicin in Leukemia (1989) Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 7: 45–49

    Google Scholar 

  52. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369

    Google Scholar 

  53. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3: 992–997

    Google Scholar 

  54. Hiddemann W, Achterrath W, Urbanitz D, Preusser P, Balleisen L, Büchner Th (1985) AMSA/Etoposid (VP 16-213). Eine Phase I/II Studie bei refraktärer akuter myeloischer Leukämie. Onkologie 8: 181–184

    Google Scholar 

  55. Hiddemann W, Martin WR, Büchner Th (1987) Definition of refractoriness to conventional therapy in advanced myeloid leukemia: An essential prerequisite for clinical phase I/II studies. Proc Am Soc Clin Oncol 6: 156

    Google Scholar 

  56. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner Th (1987) High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14: 73–77

    Google Scholar 

  57. Hiddemann W, Martin WD, Sauerland CM, Heinecke A, Büchner Th (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia — a proposal based on the results of retreatment by thioguanine, cytosine arabinoside and daunorubicin (TAD9) in 150 patients with relapse after standardized first line therapy. Leukemia (in press)

  58. Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH (1984) High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 2: 545–549

    Google Scholar 

  59. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia — an active and well-tolerated regimen. J Clin Oncol 6: 213–217

    Google Scholar 

  60. Hoelzer D, Kurrle E, Schmücker H, Harriss EB (1977) Evidence for differentiation of human leukemic blood cells in diffusion chamber culture. Blood 49: 729–744

    Google Scholar 

  61. Hoelzer D, Fliedner M (1977) Studies on the regulation of leukemic cell production in human acute leukemia. Blood Cells 3: 519–533

    Google Scholar 

  62. Von Hoff DD, Slavik M, Muggia FM (1976) 5-Azacytidine: A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85: 237–245

    Google Scholar 

  63. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I–II clinical and pharmacologic studies of highdose cytosine arabinoside in refractory leukemia. Am J Med 81: 387–394

    Google Scholar 

  64. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6: 232–238

    Google Scholar 

  65. Karp JE, Burke PJ (1986) Growth response of residual leukemia after initial drug therapy. Cancer Res 46: 4205–4207

    Google Scholar 

  66. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ (1987) Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 [Suppl 1]: 120–126

    Google Scholar 

  67. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071–1080

    Google Scholar 

  68. Keinänen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A (1988) Clonal chromosomal abnormalities showing multiple cell lineage involvement in acute myeloid leukemia. N Engl J Med 318: 1153–1158

    Google Scholar 

  69. Körbling M, Hunstein W, Fliedner TM (1984) Die autologe Knochenmarktransplantation. Dtsch Med Wochenschr 109: 265–271

    Google Scholar 

  70. Körbling M, Dörken B, Ho A, Haas R, Knauf W, Hunstein W (1990) Long-term disease free survival following autologous bone marrow / blood stem cell transplantation in 89 patients with acute leukemia. In: Büchner Th, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — Prognostic factors and treatment strategies II. Springer, Heidelberg Berlin New York Tokyo (in press)

    Google Scholar 

  71. Kolb HJ (1986) Knochenmark-Transplantation in der Bundesrepublik Deutschland. Dtsch Ärzteblatt 33: 2226–2234

    Google Scholar 

  72. Larsen RA, Sweet DL, Golomb HM, Testa JR, Rowley JD (1982) Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer 49: 2222–2225

    Google Scholar 

  73. Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood 60: 484–490

    Google Scholar 

  74. Leone G, Pagano L, Marra R, di Pietro N, Storti S, Sica S, d'Onofrio G, Ganzina F (1989) Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia. Haematologica 74: 57–61

    Google Scholar 

  75. Letendre L, Hinemann V, Hoagland HC, Kovach S (1985) Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Med Pediat Oncol 13: 232–234

    Google Scholar 

  76. Lokich J, Bothe A, Zipoli T, Green R, Sonneborn H, Paul S, Philips D (1983) Constant infusion schedule for adriamycin: A phase I–II clinical trial of a 30-day schedule by ambulatory pump delivery system. J Clin Oncol 1: 24–28

    Google Scholar 

  77. Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet I: 135–137

    Google Scholar 

  78. Marcus DE, Catovsky D, Goldman JM, Galton DAG, Newland AC, Slocombe G, Hegde U (1985) Mitoxantrone and high-dose cytarabine in adult acute myeloid leukaemia. Lancet I: 1384

    Google Scholar 

  79. Martens ACM, Schultz FW, Hagenbeek A (1987) Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 70: 1073–1078

    Google Scholar 

  80. Mitrou PS, Kuse R, Anger H, Herrmann R, Bonfert B, Pralle H, Thiel E, Westerhausen M, Mainzer K, Bartels H, Löffler H (1985) Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias. Eur J Cancer Clin Oncol 21: 919–923

    Google Scholar 

  81. Omura GA, Winton EF, Vogler WR, Zuckerman KS, Grillo-Lopez AJ (1983) Phase II study of amsacrine gluconate in refractory leukemia. Cancer Treat Rep 67: 1131–1132

    Google Scholar 

  82. Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43: 3919–3922

    Google Scholar 

  83. Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL et al. (1989) Low-dose Ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 3: 23–28

    Google Scholar 

  84. Powles RL, Palu G, McElwain TJ, Selby PJ, Morgenstern G, Clink HM, Alexander P (1979) The nature of remission in acute myeloblastic leukaemia. Lancet II: 674–676

    Google Scholar 

  85. Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP et al. (1984) Prediction of response of acute nonlymphocytic leukaemia to therapy with “high dose” cytosine arabinoside. Br J Haematol 58: 19–32

    Google Scholar 

  86. Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11: 32–35

    Google Scholar 

  87. Raghavachar A, Thiel E, Bartram CR (1987) Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 70: 1079–1083

    Google Scholar 

  88. Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Councils' 8th acute myeloid leukaemia trial. Lancet II: 1236–1241

    Google Scholar 

  89. Rowe JM, Chang AYC, Bennett JM (1990) Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood (in press)

  90. Sachs L (1977) Control of normal cell differentiation in leukemia. Israelian J Med Sci 13: 654–665

    Google Scholar 

  91. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HM (1988) Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 2: 79–83

    Google Scholar 

  92. Schaefer UW, Beelen DW, Graeven U, Kölbel M, Sayer H, Quabeck K et al. (1990) Allogeneic and autologous bone marrow transplantation in acute leukemia. Essen experience. In: Büchner Th, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — Prognostic factors and treatment strategies II. Springer, Heidelberg Berlin New York Tokyo (in press)

    Google Scholar 

  93. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR (1989) Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73: 263–270

    Google Scholar 

  94. Seshadri R, Turner DR (1986) Is maintenance therapy necessary for acute lymphoblastic leukaemia? Lancet I: 452–453

    Google Scholar 

  95. Skipper HE, Perry S (1970) Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 30: 1883–1897

    Google Scholar 

  96. Smits P, Schoots L, de Pauw BE, de Witte T, Holdrinet RSG, Janssen JTP, Haanen C (1987) Prognostic factors in adult patients with acute leukemia at first relapse. Cancer 59: 1631–1634

    Google Scholar 

  97. Takaku F, Urabe A, Mizoguchi H, Yamada O, Wakabayashi Y et al. (1985) High-dose cytosine arabinoside in the treatment of resistant acute leukemia. Semin Oncol 12 [Suppl 3]: 144–149

    Google Scholar 

  98. Tschopp L, von Fliedner VE, Sauter C, Maurice P, Gratwohl A, Fopp M, Cavalli F (1986) Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia. J Clin Oncol 4: 318–324

    Google Scholar 

  99. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA (1988) Prognostic factors in relapsed acute nonlymphocytic leukemia. Proc Am Assoc Cancer Res 29: 210

    Google Scholar 

  100. Vogler WR, Miller DS, Keller JW (1976) 5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia. Blood 48: 331–337

    Google Scholar 

  101. Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Browman G, Miller KB, Chervenick P, Azarnia N (1986) Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: A Leukemia Intergroup Study. Cancer Treat Rep 70: 455–459

    Google Scholar 

  102. de Vries EGE, Greidanus J, Mulder NH, Nieweg MB, Postmus PE, Schipper DL, Sleijfer DT, Uges DRA, Willemse PHB (1987) A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 5: 1445–1451

    Google Scholar 

  103. Warrel RP, Arlin ZA, Kempin SJ, Young CW (1982) Phase I–II evaluation of a new anthracycline antibiotic, aclacinomycin A in adults with refractory leukemia. Cancer Treat Rep 66: 1619–1623

    Google Scholar 

  104. Weh HJ, Kuse R, Hoffmann R, Seeger D, Suciu S, Kabisch H, Ritter J, Hossfeld DJ (1988) Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML). Blut 56: 19–26

    Google Scholar 

  105. Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29: 141–146

    Google Scholar 

  106. Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia. Neth J Med 26: 215–219

    Google Scholar 

  107. Winton EF, Hearn EB, Vogler WR, Johnson L, Logan T, Raney M (1983) Amsacrine in refractory adult acute leukemia: A pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 67: 977–980

    Google Scholar 

  108. Working Party on Leukaemia, European Group for Bone Marrow Transplantation (1988) Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet I: 1379–1382

    Google Scholar 

  109. Yamada K, Nakamura T, Tsuruo T, Kitahara T, Maekawa T, Uzaka Y et al. (1980) A phase II study of aclacinomycin A in acute leukemia in adults. Cancer Treat Rev 7: 177–182

    Google Scholar 

  110. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK et al. (1986) Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315: 141–147

    Google Scholar 

  111. Zittoun R, Bury J, Stryckmans P, Löwenberg B, Peetermans M, Rozendaal KY, Haanen C, Kerkhofs M, Jehn U, Willemze R (1985) Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat Rep 69: 1447–1448

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine — Hematology/Oncology, University of Münster, D-4400, Münster, Federal Republic of Germany

    W. Hiddemann & T. Büchner

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hiddemann, W., Büchner, T. Treatment strategies in acute myeloid leukemia (AML). Blut 60, 163–171 (1990). https://doi.org/10.1007/BF01720270

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01720270

Key words

Search

Navigation